Pseudomonas aeruginosa in Bronchiectasis

Laia Fernández-Barat, Victoria Alcaraz-Serrano, Rosanel Amaro, Antoni Torres

Producción científica: Artículo en revista indizadaArtículorevisión exhaustiva

7 Citas (Scopus)


Pseudomonas aeruginosa (PA) in patients with bronchiectasis (BE) is associated with a poor outcome and quality of life, and its presence is considered a marker of disease severity. This opportunistic pathogen is known for its ability to produce biofilms on biotic or abiotic surfaces and to survive environmental stress exerted by antimicrobials, inflammation, and nutrient or oxygen depletion. The presence of PA biofilms has been linked to chronic respiratory infection in cystic fibrosis but not in BE. There is considerable inconsistency in the reported infection/eradication rates of PA and chronic PA. In addition, inadequate antimicrobial treatment may potentiate the progression from intermittent to chronic infection and also the emergence of antibiotic resistance. A better comprehension of the pathophysiology of PA infections and its implications for BE is urgently needed. This can drive improvements in diagnostic accuracy, can move us toward a new consensus definition of chronic infection, can better define the follow-up of patients at risk of PA, and can achieve more successful eradication rates. In addition, the new technological advances regarding molecular diagnostics, -omics, and biomarkers require us to reconsider our traditional concepts.

Idioma originalInglés
Páginas (desde-hasta)587-594
Número de páginas8
PublicaciónSeminars in Respiratory and Critical Care Medicine
EstadoPublicada - 1 ago 2021
Publicado de forma externa


Profundice en los temas de investigación de 'Pseudomonas aeruginosa in Bronchiectasis'. En conjunto forman una huella única.

Citar esto